Multiple myeloma
Research activity is centered on newly diagnosed multiple myeloma in older adults, with particular attention to treatment strategies for patients aged 70 years and above. The clinical focus includes disease control in a population with age-related treatment considerations and the use of monoclonal antibody-based regimens in haematologic malignancy.
- Newly diagnosed multiple myeloma
- Elderly patients
- Haematologic oncology
The sponsor’s trial portfolio reflects interest in improving outcomes for older patients with plasma cell disorders, including disease response assessment and deeper remission endpoints such as minimal residual disease negativity.
Immunotherapy and antibody-based treatment
The funded research includes the use of isatuximab, highlighting a therapeutic interest in anti-CD38 antibody approaches for myeloma. This area connects immune-targeted therapy with standard anti-myeloma treatment backbones such as lenalidomide and dexamethasone.
- Isatuximab
- Anti-CD38 therapy
- Combination immunotherapy
Research interest extends to treatment combinations that integrate immune-directed agents with established anti-myeloma therapies in order to address both frontline disease control and longer-term maintenance needs.
Maintenance therapy and remission depth
A key therapeutic domain is maintenance therapy after initial treatment, with emphasis on sustaining disease control in multiple myeloma. The study focus includes response depth and the proportion of patients achieving MRD negativity as a clinically meaningful endpoint.
- Maintenance treatment
- MRD negativity
- Response depth
This area reflects interest in prolonged disease suppression and treatment strategies that extend beyond induction therapy into ongoing management of plasma cell neoplasms.
